<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35335346</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-3049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecules (Basel, Switzerland)</Title>
          <ISOAbbreviation>Molecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Positive Effect of α-Asaronol on the Incidence of Post-Stroke Epilepsy for Rat with Cerebral Ischemia-Reperfusion Injury.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1984</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27061984</ELocationID>
        <Abstract>
          <AbstractText>In the present study, we confirmed that α-asaronol, which is a product of the active metabolites of alpha Asarone, did not affect n-butylphthalide efficacy when n-butylphthalide and α-asaronol were co-administered to rats with cerebral ischemia-reperfusion injury. Our research revealed that the co-administration of α-asaronol and n-butylphthalide could further improve neurological function, reduce brain infarct volume, increase the number of Nissl bodies, and decrease the ratios of apoptotic cells and the expression of the caspase-3 protein for cerebral ischemia-reperfusion injury model compared to n-butylphthalide alone. Additionally, α-asaronol could significantly decrease the incidence of post-stroke epilepsy versus n-butylphthalide. This study provides valuable data for the follow-up prodrug research of α-asaronol and n-butylphthalide.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Lan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Environment and Resources, Chongqing Technology and Business University, Chongqing 400067, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xiangnan</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-3654-4734</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Molecules</MedlineTA>
        <NlmUniqueID>100964009</NlmUniqueID>
        <ISSNLinking>1420-3049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000840">Anisoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000712277">alpha-asaronol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000840" MajorTopicYN="N">Anisoles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015427" MajorTopicYN="Y">Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ischemic stroke</Keyword>
        <Keyword MajorTopicYN="N">n-butylphthalide</Keyword>
        <Keyword MajorTopicYN="N">post-stroke epilepsy</Keyword>
        <Keyword MajorTopicYN="N">α-asaronol</Keyword>
      </KeywordList>
      <CoiStatement>The sponsors had no role in the design, execution, interpretation, or writing of the study. The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>1</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35335346</ArticleId>
        <ArticleId IdType="pmc">PMC8952411</ArticleId>
        <ArticleId IdType="doi">10.3390/molecules27061984</ArticleId>
        <ArticleId IdType="pii">molecules27061984</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>GBD 2016 Stroke Collaborators  Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–458. doi: 10.1016/S1474-4422(19)30034-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(19)30034-1</ArticleId>
            <ArticleId IdType="pmc">PMC6494974</ArticleId>
            <ArticleId IdType="pubmed">30871944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Bian D., Yu J., Li M., Zhao D. Using machine learning models to improve stroke risk level classification methods of China national stroke screening. BMC Med. Inform. Decis. Mak. 2019;19:261.  doi: 10.1186/s12911-019-0998-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12911-019-0998-2</ArticleId>
            <ArticleId IdType="pmc">PMC6902572</ArticleId>
            <ArticleId IdType="pubmed">31822270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah F.A., Li T., Kury L.T.A., Zeb A., Khatoon S., Liu G., Yang X., Liu F., Yao H., Khan A.U., et al.  Pathological Comparisons of the Hippocampal Changes in the Transient and Permanent Middle Cerebral Artery Occlusion Rat Models. Front. Neurol. 2019;10:1178. doi: 10.3389/fneur.2019.01178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.01178</ArticleId>
            <ArticleId IdType="pmc">PMC6868119</ArticleId>
            <ArticleId IdType="pubmed">31798514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guekht A., Bornstein N.M. Seizures after stroke. Handb. Clin. Neurol. 2012;108:569–583. doi: 10.1016/B978-0-444-52899-5.00016-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-52899-5.00016-2</ArticleId>
            <ArticleId IdType="pubmed">22939054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie W.J., Dong M., Liu Q., Meng H.M. Early predictors and prevention for post-stroke epilepsy: Changes in neurotransmitter levels. Transl. Neurosci. 2016;7:1–5. doi: 10.1515/tnsci-2016-0001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/tnsci-2016-0001</ArticleId>
            <ArticleId IdType="pmc">PMC5017595</ArticleId>
            <ArticleId IdType="pubmed">28123814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Li X., Zhang K., Tong T., Cui R. The Progress of Epilepsy after Stroke. Curr. Neuropharmacol. 2018;16:71–78. doi: 10.2174/1570159X15666170613083253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X15666170613083253</ArticleId>
            <ArticleId IdType="pmc">PMC5771387</ArticleId>
            <ArticleId IdType="pubmed">28606039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bladin C.F., Alexandrov A.V., Bellavance A., Bornstein N., Chambers B., Coté R., Lebrun L., Pirisi A., Norris J.W. Seizures after stroke: A prospective multicenter study. Arch. Neurol. 2000;57:1617–1622. doi: 10.1001/archneur.57.11.1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.57.11.1617</ArticleId>
            <ArticleId IdType="pubmed">11074794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velioğlu S.K., Ozmenoğlu M., Boz C., Alioğlu Z. Status epilepticus after stroke. Stroke. 2001;32:1169–1172. doi: 10.1161/01.STR.32.5.1169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.32.5.1169</ArticleId>
            <ArticleId IdType="pubmed">11340227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse E.J., Vaughan J.K., Barnes T.Y., Boggs J.G., Towne A.R., Kopec-Garnett L., DeLorenzo R.J. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res. 1998;29:175–183. doi: 10.1016/S0920-1211(97)00071-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0920-1211(97)00071-5</ArticleId>
            <ArticleId IdType="pubmed">9551779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtkamp M., Beghi E., Benninger F., Kälviäinen R., Rocamora R., Christensen H. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur. Stroke J. 2017;2:103–115. doi: 10.1177/2396987317705536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2396987317705536</ArticleId>
            <ArticleId IdType="pmc">PMC6453212</ArticleId>
            <ArticleId IdType="pubmed">31008306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgenstern L.B., Hemphill J.C., Anderson C., Becker K., Broderick J.P., Connolly E.S., Greenberg S.M., Huang J.N., MacDonald R.L., Messé S.R., et al.  Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–2129. doi: 10.1161/STR.0b013e3181ec611b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STR.0b013e3181ec611b</ArticleId>
            <ArticleId IdType="pmc">PMC4462131</ArticleId>
            <ArticleId IdType="pubmed">20651276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidech A.M., Garg R.K., Liebling S., Levasseur K., Macken M.P., Schuele S.U., Batjer H.H. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009;40:3810–3815. doi: 10.1161/STROKEAHA.109.559948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.109.559948</ArticleId>
            <ArticleId IdType="pubmed">19797183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Temkin N.R., Dikmen S.S., Anderson G.D., Wilensky A.J., Holmes M.D., Cohen W., Newell D.W., Nelson P., Awan A., Winn H.R. Valproate therapy for prevention of posttraumatic seizures: A randomized trial. J. Neurosurg. 1999;91:593–600. doi: 10.3171/jns.1999.91.4.0593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.1999.91.4.0593</ArticleId>
            <ArticleId IdType="pubmed">10507380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L.Y., Hu M.B., Li R.L., Zhao R., Fan L.H., Wang L., Peng W., Liu Y.J., Wu C.J. The Effect of Protein-Rich Extract from Bombyx Batryticatus against Glutamate-Damaged PC12 Cells Via Regulating γ-Aminobutyric Acid Signaling Pathway. Molecules. 2020;25:553.  doi: 10.3390/molecules25030553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules25030553</ArticleId>
            <ArticleId IdType="pmc">PMC7037904</ArticleId>
            <ArticleId IdType="pubmed">32012896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Z.T., Shi X.J., Yuan Y.X., Qiu Y.Y., Zou Y., Liu C., Yu H., He X., Xu K., Yin P.H. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget. 2017;8:48012–48026. doi: 10.18632/oncotarget.18225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18225</ArticleId>
            <ArticleId IdType="pmc">PMC5564622</ArticleId>
            <ArticleId IdType="pubmed">28624793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Wu Z.M., Yang Y.P., Shaukat A., Yang J., Guo Y.F., Zhang T., Zhu X.Y., Qiu J.X., Deng G.Z., et al.  Catalpol ameliorates LPS-induced endometritis by inhibiting inflammation and TLR4/NF-κB signaling. J. Zhejiang Univ. Sci. B. 2019;20:816–827. doi: 10.1631/jzus.B1900071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1631/jzus.B1900071</ArticleId>
            <ArticleId IdType="pmc">PMC6751487</ArticleId>
            <ArticleId IdType="pubmed">31489801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C., Li W.G., Zhang X.B., Wang L., Xu T.L., Wu D., Li Y. α-asarone from Acorus gramineus alleviates epilepsy by modulating A-type GABA receptors. Neuropharmacology. 2013;65:1–11. doi: 10.1016/j.neuropharm.2012.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2012.09.001</ArticleId>
            <ArticleId IdType="pubmed">22975146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z.J., Levinson S.R., Sun L., Heinbockel T. Identification of both GABAA receptors and voltage-activated Na (+) channels as molecular targets of anticonvulsant α-asarone. Front. Pharmacol. 2014;5:40. doi: 10.3389/fphar.2014.00040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2014.00040</ArticleId>
            <ArticleId IdType="pmc">PMC3949418</ArticleId>
            <ArticleId IdType="pubmed">24653701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cartus A.T., Schrenk D. Metabolism of the carcinogen alpha-asarone in liver microsomes. Food Chem. Toxicol. 2016;87:103–112. doi: 10.1016/j.fct.2015.11.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2015.11.021</ArticleId>
            <ArticleId IdType="pubmed">26678343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He X., Bai Y., Zeng M., Zhao Z., Zhang Q., Xu N., Qin F., Wei X., Zhao M., Wu N., et al.  Anticonvulsant activities of α-asaronol ((E)-3’-hydroxyasarone), an active constituent derived from α-asarone. Pharmacol. Rep. 2018;70:69–74. doi: 10.1016/j.pharep.2017.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharep.2017.08.004</ArticleId>
            <ArticleId IdType="pubmed">29331789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Q.Y., Zhang H., Zhang X., He D.S., Wang S.W., Cao X., Dai Y.T., Xu Y., Han L.-J. dl-3-n-butylphthalide preserves white matter integrity and alleviates cognitive impairment in mice with chronic cerebral hypoperfusion. CNS Neurosci. Ther. 2019;25:1042–1053. doi: 10.1111/cns.13189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cns.13189</ArticleId>
            <ArticleId IdType="pmc">PMC6698981</ArticleId>
            <ArticleId IdType="pubmed">31334611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong Z., Lu W., Zhu L., Zeng L., Shi C., Jing Z., Xiang Y., Li W., Tsang C.K., Ruan Y., et al.  Dl-3-n-Butylphthalide Treatment Enhances Hemodynamics and Ameliorates Memory Deficits in Rats with Chronic Cerebral Hypoperfusion. Front. Aging Neurosci. 2017;9:238. doi: 10.3389/fnagi.2017.00238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2017.00238</ArticleId>
            <ArticleId IdType="pmc">PMC5526838</ArticleId>
            <ArticleId IdType="pubmed">28798681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., Li G., Zhao D., Yang P., Shabier T., Tuerxun T. Association between IL-1β and recurrence after the first epileptic seizure in ischemic stroke patients. Sci. Rep. 2020;10:13505. doi: 10.1038/s41598-020-70560-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-70560-7</ArticleId>
            <ArticleId IdType="pmc">PMC7419303</ArticleId>
            <ArticleId IdType="pubmed">32782321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H., Rajah G., Guo A., Wang Y., Wang Q. Pathogenesis of epileptic seizures and epilepsy after stroke. Neurol. Res. 2018;40:426–432. doi: 10.1080/01616412.2018.1455014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01616412.2018.1455014</ArticleId>
            <ArticleId IdType="pubmed">29681214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M., Li B., Lv X., Liu S., Liu Y., Tang R., Lang Y., Huang Q., He J. Low-Intensity Focused Ultrasound-Mediated Attenuation of Acute Seizure Activity Based on EEG Brain Functional Connectivity. Brain Sci. 2021;11:711.  doi: 10.3390/brainsci11060711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/brainsci11060711</ArticleId>
            <ArticleId IdType="pmc">PMC8228165</ArticleId>
            <ArticleId IdType="pubmed">34071964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N., Liu G.t. The novel squamosamide derivative FLZ enhances BDNF/TrkB/CREB signaling and inhibits neuronal apoptosis in APP/PS1 mice. Acta Pharmacol. Sin. 2010;31:265–272. doi: 10.1038/aps.2010.3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2010.3</ArticleId>
            <ArticleId IdType="pmc">PMC4002416</ArticleId>
            <ArticleId IdType="pubmed">20154710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng W.S., Lin I.H., Feng K.M., Chang Z.Y., Huang Y.C., Lu D.W. Neuroprotective effects of exogenous erythropoietin in Wistar rats by downregulating apoptotic factors to attenuate N-methyl-D-aspartate-mediated retinal ganglion cells death. PLoS ONE. 2020;15:e0223208.  doi: 10.1371/journal.pone.0223208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0223208</ArticleId>
            <ArticleId IdType="pmc">PMC7164594</ArticleId>
            <ArticleId IdType="pubmed">32302311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37–43. doi: 10.1038/376037a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/376037a0</ArticleId>
            <ArticleId IdType="pubmed">7596430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krajewska M., Wang H.G., Krajewski S., Zapata J.M., Shabaik A., Gascoyne R., Reed J.C. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res. 1997;57:1605–1613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9108467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai M., Nagata T., Abe K., Horinouchi T., Itoyama Y., Tabayashi K. Survival and death-promoting events after transient spinal cord ischemia in rabbits: Induction of Akt and caspase3 in motor neurons. J. Thorac. Cardiovasc. Surg. 2003;125:370–377. doi: 10.1067/mtc.2003.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mtc.2003.112</ArticleId>
            <ArticleId IdType="pubmed">12579107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito E., Li W., Mandeville E.T., Park J.H., Şencan I., Guo S., Shi J., Lan J., Lee J., Hayakawa K., et al.  Potential circadian effects on translational failure for neuroprotection. Nature. 2020;582:395–398. doi: 10.1038/s41586-020-2348-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2348-z</ArticleId>
            <ArticleId IdType="pubmed">32494010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91. doi: 10.1161/01.STR.20.1.84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.20.1.84</ArticleId>
            <ArticleId IdType="pubmed">2643202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005–1011. doi: 10.1161/01.STR.32.4.1005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.32.4.1005</ArticleId>
            <ArticleId IdType="pubmed">11283404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khamse S., Sadr S.S., Roghani M., Hasanzadeh G., Mohammadian M. Rosmarinic acid exerts a neuroprotective effect in the kainate rat model of temporal lobe epilepsy: Underlying mechanisms. Pharm. Biol. 2015;53:1818–1825. doi: 10.3109/13880209.2015.1010738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/13880209.2015.1010738</ArticleId>
            <ArticleId IdType="pubmed">25874386</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
